{"id":"NCT03290781","sponsor":"Shire","briefTitle":"An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis","officialTitle":"A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-04","primaryCompletion":"2021-07-01","completion":"2021-07-01","firstPosted":"2017-09-25","resultsPosted":"2022-01-14","lastUpdate":"2022-01-14"},"enrollment":366,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Ontamalimab","otherNames":["PF-00547659","SHP647"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ontamalimab 25 mg","type":"EXPERIMENTAL"},{"label":"Ontamalimab 75 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of ontamalimab as maintenance therapy treatment of remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).","primaryOutcome":{"measure":"Number of Participants With Remission Based on Composite Score at Week 52","timeFrame":"At Week 52","effectByArm":[{"arm":"ONTA 25 mg/ Placebo","deltaMin":6,"sd":null},{"arm":"ONTA 25 mg/ONTA 25 mg","deltaMin":38,"sd":null},{"arm":"ONTA 75 mg/Placebo","deltaMin":11,"sd":null},{"arm":"ONTA 75 mg/ONTA 75 mg","deltaMin":33,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG002 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":401,"countries":["United States","Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Bulgaria","Canada","Colombia","Croatia","Czechia","Estonia","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Lebanon","Lithuania","Mexico","Netherlands","New Zealand","Poland","Portugal","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Switzerland","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["38096402"],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b5fdf4db2bf003ab47502"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":73},"commonTop":["Colitis ulcerative","Nasopharyngitis","Arthralgia","Headache","Abdominal pain"]}}